SOX15

Summary

SOX15 (SRY-box transcription factor 15, HGNC:11196) is a protein-coding gene on chromosome 17p13.1, encoding Transcription factor SOX-15 (O60248). Transcription factor that binds to DNA at the 5’-AACAATG-3’ consensus sequence.

This gene encodes a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate. The encoded protein may act as a transcriptional regulator after forming a protein complex with other proteins.

Source: NCBI Gene 6665 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 36 total
• MANE Select transcript: NM_006942

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11196
Approved symbol	SOX15
Name	SRY-box transcription factor 15
Location	17p13.1
Locus type	gene with protein product
Status	Approved
Aliases	SOX27, SOX26
Ensembl gene	ENSG00000129194
Ensembl biotype	protein_coding
OMIM	601297
Entrez	6665

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000250055, ENST00000538513, ENST00000570788

RefSeq mRNA: 1 — MANE Select: NM_006942 NM_006942

CCDS: CCDS32549

Canonical transcript exons

ENST00000250055 — 2 exons

Exon	Start	End
ENSE00000887339	7589144	7590094
ENSE00001319870	7588178	7588546

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 96.92.

FANTOM5 (CAGE): breadth broad, TPM avg 13.0827 / max 470.6203, expressed in 807 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164262	6.8008	290
164260	6.0726	754
164259	0.2094	124

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	96.92	gold quality
oocyte	CL:0000023	95.61	gold quality
esophagus mucosa	UBERON:0002469	94.77	gold quality
secondary oocyte	CL:0000655	92.30	gold quality
skin of abdomen	UBERON:0001416	90.56	gold quality
skin of leg	UBERON:0001511	89.35	gold quality
cervix squamous epithelium	UBERON:0006922	88.42	silver quality
pharyngeal mucosa	UBERON:0000355	87.92	gold quality
esophagus	UBERON:0001043	87.88	gold quality
zone of skin	UBERON:0000014	87.79	gold quality
vagina	UBERON:0000996	87.54	gold quality
tongue squamous epithelium	UBERON:0006919	87.15	silver quality
right hemisphere of cerebellum	UBERON:0014890	86.79	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	86.75	gold quality
cerebellar hemisphere	UBERON:0002245	86.51	gold quality
cerebellar cortex	UBERON:0002129	86.40	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.14	gold quality
squamous epithelium	UBERON:0006914	85.98	silver quality
epithelium of esophagus	UBERON:0001976	85.83	silver quality
cerebellum	UBERON:0002037	85.65	gold quality
Brodmann (1909) area 10	UBERON:0013541	85.48	gold quality
esophagus squamous epithelium	UBERON:0006920	85.02	silver quality
cingulate cortex	UBERON:0003027	84.90	gold quality
anterior cingulate cortex	UBERON:0009835	84.88	gold quality
gingiva	UBERON:0001828	84.75	gold quality
gingival epithelium	UBERON:0001949	84.74	silver quality
paraflocculus	UBERON:0005351	83.93	gold quality
mammalian vulva	UBERON:0000997	83.70	gold quality
right frontal lobe	UBERON:0002810	83.64	gold quality
mucosa of stomach	UBERON:0001199	83.39	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-86618	no	40.73
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
FOXK1	Unknown
HRC

JASPAR motifs

Motif	Name	Family
MA1152.1	SOX15	SOX-related factors
MA1152.2	SOX15	SOX-related factors

JASPAR matrix evidence (PMIDs): PMID:15863505

miRNA regulators (miRDB)

27 targeting SOX15, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-12113	99.32	67.54	1072
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-4539	98.78	67.18	888
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-2681-3P	98.18	65.28	577
HSA-MIR-4768-3P	98.16	66.02	2330
HSA-MIR-1287-5P	96.80	65.30	743
HSA-MIR-6839-5P	96.74	68.29	1088
HSA-MIR-378J	96.44	66.20	1020

Literature-anchored findings (GeneRIF, showing 12)

• We established stable NT2/D1 cell lines overexpressing SOX15 (SOX15-NT2/D1), and a modified 3-(4,5-dime-thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that the SOX15-NT2/D1 cells exhibited significantly slower growth than controls (PMID:18182846)
• The gain of function studies indicated that sex-determining region Y (SRY)-box 15 (SOX15) activate NR5A1 gene expression. (PMID:18579725)
• Results indicate that the expression of SOX15 in pancreatic cancer cell lines with undetectable expression resulted in reduced viability of cancer cells both in vitro and in vivo demonstrating its tumor suppressive capability. (PMID:23318427)
• Increased expression of epithelial OCT4, SOX15 and TWIST1 was detected in endometriotic tissue compared to endometriosis patient endometrium. Epithelial expression of OCT4, SOX15, and TWIST1 was increased in the endometrium of endometriosis patients compared to controls. (PMID:27881125)
• SOX15 can be a tumor suppressor in colorectal cancer by suppressing the Wnt-beta-catenin signaling pathway. (PMID:30019915)
• the current study revealed that inhibition of SOX15 in ESCC cells sensitizes the ESCC cells to paclitaxel, suggesting that the SOX15 expression level may predict the therapeutic outcomes for paclitaxel treatment for ESCC. (PMID:30950353)
• Downregulation of microR-147b represses the proliferation and invasion of thyroid carcinoma cells by inhibiting Wnt/beta-catenin signaling via targeting SOX15. (PMID:31760045)
• These data demonstrate that SOX15 functions as a potential tumor-suppressor in glioma by inhibiting cell proliferation and invasion via the downregulation of Wnt/beta-catenin signaling (PMID:32416168)
• Epigenetic Silencing of SOX15 Is Controlled by miRNAs rather than Methylation in Papillary Thyroid Cancer. (PMID:34603557)
• SOX15 transcriptionally increases the function of AOC1 to modulate ferroptosis and progression in prostate cancer. (PMID:35922412)
• [The Mechanism of miR-1294 Targeting SOX15 to Regulate Wnt/beta-catenin Signaling Pathway and Promote the Proliferation of Acute Lymphoblastic Leukemia Cells in Children]. (PMID:37096504)
• CircVPS8 promotes the malignant phenotype and inhibits ferroptosis of glioma stem cells by acting as a scaffold for MKRN1, SOX15 and HNF4A. (PMID:39098847)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	sox19a	ENSDARG00000010770
danio_rerio	sox19b	ENSDARG00000040266
danio_rerio	sox32	ENSDARG00000100591
mus_musculus	Sox15	ENSMUSG00000041287
rattus_norvegicus	Sox15	ENSRNOG00000012155
drosophila_melanogaster	Sox14	FBGN0005612
drosophila_melanogaster	Sox15	FBGN0005613
drosophila_melanogaster	Sox100B	FBGN0024288
drosophila_melanogaster	Sox21a	FBGN0036411
drosophila_melanogaster	Sox102F	FBGN0039938
caenorhabditis_elegans		WBGENE00001182
caenorhabditis_elegans		WBGENE00015716

Paralogs (20): SOX8 (ENSG00000005513), SOX30 (ENSG00000039600), SOX10 (ENSG00000100146), SOX6 (ENSG00000110693), SOX4 (ENSG00000124766), SOX21 (ENSG00000125285), SOX9 (ENSG00000125398), SOX5 (ENSG00000134532), SOX3 (ENSG00000134595), SOX13 (ENSG00000143842), SOX17 (ENSG00000164736), SOX14 (ENSG00000168875), SOX7 (ENSG00000171056), SOX11 (ENSG00000176887), SOX12 (ENSG00000177732), CFAP65 (ENSG00000181378), SOX2 (ENSG00000181449), SOX1 (ENSG00000182968), SRY (ENSG00000184895), SOX18 (ENSG00000203883)

Protein

Protein identifiers

Transcription factor SOX-15 — O60248 (reviewed: O60248)

Alternative names: Protein SOX-12, Protein SOX-20, SRY-box transcription factor 15

All UniProt accessions (1): O60248

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that binds to DNA at the 5’-AACAATG-3’ consensus sequence. Acts as a transcriptional activator and repressor. Binds synergistically with POU5F1 (OCT3/4) to gene promoters. Binds to the FOXK1 promoter and recruits FHL3, resulting in transcriptional activation of FOXK1 which leads to myoblast proliferation. Acts as an inhibitor of myoblast differentiation via transcriptional repression which leads to down-regulation of the muscle-specific genes MYOD and MYOG. Involved in trophoblast giant cell differentiation via enhancement of HAND1 transcriptional activity. Regulates transcription of HRC via binding to it proximal enhancer region. Involved in skeletal muscle regeneration. Also plays a role in the development of myogenic precursor cells.

Subunit / interactions. Interacts with HAND1; the interaction enhances HAND1-induced differentiation of trophoblast giant cells. Interacts with POU5F1 (OCT3/4); binds synergistically with POU5F1 to DNA. Interacts with FHL3; the interaction recruits the transcriptional coactivator FHL3 to the FOXK1 promoter.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed in fetal and adult tissues examined, highest level found in fetal spinal cord and adult brain and testis.

Isoforms (2)

UniProt ID	Names	Canonical?
O60248-1	1	yes
O60248-2	2

RefSeq proteins (1): NP_008873* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009071	HMG_box_dom	Domain
IPR036910	HMG_box_dom_sf	Homologous_superfamily
IPR050140	SRY-related_HMG-box_TF-like	Family

Pfam: PF00505

UniProt features (16 total): sequence conflict 5, region of interest 5, compositionally biased region 2, chain 1, DNA-binding region 1, splice variant 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60248-F1	69.14	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 37

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 163 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, FXR_IR1_Q6, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_SKELETAL_MUSCLE_TISSUE_REGENERATION, HNF3ALPHA_Q6, RORA1_01, JAEGER_METASTASIS_DN, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, GCANCTGNY_MYOD_Q6, DAZARD_UV_RESPONSE_CLUSTER_G4, NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER, GOBP_GROWTH, GOBP_REGENERATION, GOBP_NEUROGENESIS

GO Biological Process (16): negative regulation of transcription by RNA polymerase II (GO:0000122), chromatin organization (GO:0006325), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), brain development (GO:0007420), male gonad development (GO:0008584), positive regulation of satellite cell activation involved in skeletal muscle regeneration (GO:0014718), cell differentiation (GO:0030154), neuron differentiation (GO:0030182), skeletal muscle tissue regeneration (GO:0043403), negative regulation of striated muscle tissue development (GO:0045843), positive regulation of transcription by RNA polymerase II (GO:0045944), myoblast development (GO:0048627), trophoblast giant cell differentiation (GO:0060707), positive regulation of G0 to G1 transition (GO:0070318), positive regulation of myoblast proliferation (GO:2000288)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), transcription regulator complex (GO:0005667), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of DNA-templated transcription	2
binding	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
cellular component organization	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
central nervous system development	1
animal organ development	1
head development	1
gonad development	1
development of primary male sexual characteristics	1
regulation of satellite cell activation involved in skeletal muscle regeneration	1
satellite cell activation involved in skeletal muscle regeneration	1
positive regulation of skeletal muscle tissue regeneration	1
positive regulation of cell activation	1
cellular developmental process	1
cell differentiation	1
generation of neurons	1
tissue regeneration	1
striated muscle tissue development	1
regulation of striated muscle tissue development	1
negative regulation of muscle organ development	1
negative regulation of muscle tissue development	1
positive regulation of DNA-templated transcription	1
myoblast differentiation	1
cell development	1
cell differentiation involved in embryonic placenta development	1
G0 to G1 transition	1
regulation of G0 to G1 transition	1
positive regulation of cell cycle process	1
positive regulation of cell population proliferation	1
myoblast proliferation	1
regulation of myoblast proliferation	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

28 interactions, top by confidence:

A	B	Type	Score
BHLHE40	SOX15	psi-mi:“MI:0915”(physical association)	0.560
HSFY1	SOX15	psi-mi:“MI:0915”(physical association)	0.560
HOXB9	SOX15	psi-mi:“MI:0915”(physical association)	0.520
NFIA	SOX15	psi-mi:“MI:0915”(physical association)	0.470
NFIB	SOX15	psi-mi:“MI:0915”(physical association)	0.470
NFIC	SOX15	psi-mi:“MI:0915”(physical association)	0.400
SOX15	PPP3R1	psi-mi:“MI:0915”(physical association)	0.400
CFTR	SOX15	psi-mi:“MI:0915”(physical association)	0.370
SOX15	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
	POLR3A	psi-mi:“MI:0914”(association)	0.350
	DDX3X	psi-mi:“MI:0914”(association)	0.350
	HNRNPDL	psi-mi:“MI:0914”(association)	0.350
	GTPBP10	psi-mi:“MI:0914”(association)	0.350
	PES1	psi-mi:“MI:0914”(association)	0.350
	IGF2BP3	psi-mi:“MI:0914”(association)	0.350
	EIF3F	psi-mi:“MI:0914”(association)	0.350
	ESYT2	psi-mi:“MI:0914”(association)	0.350
SOX15	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (154): BHLHE40 (Two-hybrid), HSFY1 (Two-hybrid), PPP3R1 (Affinity Capture-MS), HOXB9 (Proximity Label-MS), KDM6A (Proximity Label-MS), POU2F1 (Proximity Label-MS), FOXK1 (Proximity Label-MS), FOXP1 (Proximity Label-MS), TRPS1 (Proximity Label-MS), ZNF281 (Proximity Label-MS), SATB1 (Proximity Label-MS), SMCHD1 (Proximity Label-MS), BCL9 (Proximity Label-MS), NFIB (Proximity Label-MS), ARID1A (Proximity Label-MS)

ESM2 similar proteins: A1YF56, A2AEV7, A6NCS4, A7Y7W2, D3ZJK7, E1BEA8, F1MUS9, O15534, O35973, O43435, O43638, O60248, O75333, O77728, O94983, O95935, O95947, P22736, P46099, P51666, P56261, P57082, P70325, P70327, Q03484, Q0V8F0, Q15744, Q497V6, Q5DTT2, Q61660, Q61663, Q63HR2, Q64731, Q66JL1, Q6PZD9, Q6ZQN5, Q80Y50, Q810F8, Q861Q9, Q8AV66

Diamond homologs: A2TED3, A4QNG3, B0ZTE1, B0ZTE2, O00570, O42569, O57401, O60248, O95416, P36389, P36390, P36393, P36395, P36396, P41225, P43267, P47792, P48046, P48430, P48431, P48432, P48433, P51501, P53783, P53784, P54231, P55863, P61259, Q04892, Q05066, Q20201, Q21305, Q24533, Q28447, Q28778, Q28783, Q28798, Q2PG84, Q2Z1R2, Q32PP9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

242 predictions. Top by Δscore:

Variant	Effect	Δscore
17:7589142:AC:A	donor_gain	0.9900
17:7589143:CC:C	donor_gain	0.9900
17:7589136:GCACT:G	donor_loss	0.9800
17:7589137:CACTC:C	donor_loss	0.9800
17:7589138:ACTC:A	donor_loss	0.9800
17:7589139:CT:C	donor_loss	0.9800
17:7589140:TCA:T	donor_loss	0.9800
17:7589141:CACC:C	donor_loss	0.9800
17:7589142:A:AC	donor_gain	0.9800
17:7589143:C:CC	donor_gain	0.9800
17:7589267:C:A	donor_gain	0.9800
17:7589135:GGCAC:G	donor_loss	0.9700
17:7588547:C:CC	acceptor_gain	0.9500
17:7588740:G:A	donor_gain	0.9300
17:7589149:G:C	donor_gain	0.9300
17:7589194:AAAG:A	donor_gain	0.9300
17:7589266:T:TA	donor_gain	0.9300
17:7589187:TG:T	donor_gain	0.9100
17:7588545:AGC:A	acceptor_loss	0.9000
17:7588547:C:A	acceptor_loss	0.9000
17:7588548:T:A	acceptor_loss	0.9000
17:7588543:AGAG:A	acceptor_gain	0.8800
17:7588549:G:C	acceptor_loss	0.8800
17:7588656:AG:A	donor_gain	0.8800
17:7588544:GAG:G	acceptor_gain	0.8700
17:7589142:ACC:A	donor_gain	0.8700
17:7589143:CCC:C	donor_gain	0.8700
17:7588650:C:CT	donor_gain	0.8300
17:7588651:T:TT	donor_gain	0.8300
17:7588556:GAAA:G	acceptor_loss	0.8100

AlphaMissense

1470 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:7589416:C:A	W87C	1.000
17:7589416:C:G	W87C	1.000
17:7589418:A:G	W87R	1.000
17:7589418:A:T	W87R	1.000
17:7589500:C:A	W59C	1.000
17:7589500:C:G	W59C	1.000
17:7589502:A:G	W59R	1.000
17:7589502:A:T	W59R	1.000
17:7589507:A:G	M57T	1.000
17:7589509:G:C	F56L	1.000
17:7589509:G:T	F56L	1.000
17:7589510:A:C	F56C	1.000
17:7589510:A:G	F56S	1.000
17:7589511:A:G	F56L	1.000
17:7589511:A:T	F56I	1.000
17:7589515:G:C	N54K	1.000
17:7589515:G:T	N54K	1.000
17:7589324:T:C	Y118C	0.999
17:7589325:A:G	Y118H	0.999
17:7589352:G:C	H109D	0.999
17:7589363:A:G	L105P	0.999
17:7589373:C:G	A102P	0.999
17:7589383:G:C	F98L	0.999
17:7589383:G:T	F98L	0.999
17:7589385:A:G	F98L	0.999
17:7589392:C:A	K95N	0.999
17:7589392:C:G	K95N	0.999
17:7589417:C:G	W87S	0.999
17:7589429:A:G	L83P	0.999
17:7589432:C:G	R82P	0.999

dbSNP variants (sampled 300 via entrez): RS1000051307 (17:7589842 G>T), RS1000166807 (17:7589572 A>G), RS1000424656 (17:7587890 G>C), RS1001623371 (17:7590929 G>T), RS1002170983 (17:7591391 C>T), RS1002285461 (17:7591116 TGAAGA>T), RS1003060823 (17:7587952 G>A), RS1003317176 (17:7589905 G>A,T), RS1003629912 (17:7590162 C>A), RS1004007403 (17:7591456 TGGGAGGAGGGATAGCAG>T), RS1004065561 (17:7589212 G>A), RS1006180153 (17:7591522 C>A,G,T), RS1006358467 (17:7590261 C>G), RS1007068987 (17:7590460 G>T), RS1007860701 (17:7588708 G>A,C)

Disease associations

OMIM: gene MIM:601297 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006414_33	Atrial fibrillation	2.000000e-09
GCST010703_158	Brain morphology (MOSTest)	3.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Decitabine	decreases expression, decreases reaction, decreases methylation, increases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	2
Smoke	decreases expression, decreases reaction	2
Valproic Acid	decreases expression, increases methylation	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
beta-lapachone	decreases expression	1
methylparaben	increases expression	1
sulforaphane	decreases expression	1
sodium arsenite	decreases expression	1
butylparaben	increases expression	1
isobutyl alcohol	affects cotreatment, increases abundance, increases expression	1
JP8 aviation fuel	increases expression	1
chloropicrin	decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Carbamazepine	affects expression	1
Diethylhexyl Phthalate	increases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Polycyclic Aromatic Hydrocarbons	increases expression, affects cotreatment, increases abundance	1
Silver	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cadmium Chloride	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6M0	SEES3-1V human SOX15, clone1	Embryonic stem cell	Male
CVCL_A6M1	SEES3-1V human SOX15, clone2	Embryonic stem cell	Male
CVCL_A6M2	SEES3-1V human SOX15, clone3	Embryonic stem cell	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.